To investigate the correlations between HMGB2 expression and clinicopathological factors in cervical cancer, the expression level of HMGB2 was represented with an immunoreactive scored (IRS; 3, strong; 2, moderate; 1, weak; 0, negative). Here, HMGB2 is linked to cervical cancer.